当前位置: 首页 > 期刊 > 《中国药房》 > 201924
编号:13523508
度洛西汀治疗重性抑郁障碍有效性与安全性的Meta分析(5)
http://www.100md.com 2019年12月15日 《中国药房》 201924
     [19] BOULENGER JP,LOFT H,OLSEN CK. Efficacy and safety of vortioxetine(Lu AA21004),15 and 20 mg/day:a randomized,double-blind,placebo-controlled,duloxetine- referenced study in the acute treatment of adult patients with major depressive disorder[J]. Int Clin Psychopharmacol,2014,29(3):138-149.

    [20] MAHABLESHWARKAR AR,JACOBSEN PL,CHEN Y,et al. A randomized,double-blind,duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD[J]. Psychopharmacology:Berl,2015,232(12):2061- 2070.

    [21] MAHABLESHWARKAR AR,ZAJECKA J,JACOBSON W,et al. A randomized,placebo-controlled,active-refe- rence,double-blind,flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder[J]. Neuropsychopharmacology,2015,40(8):2025- 2037.

    [22] WANG L,AN J,GAO HM,et al. Duloxetine effects on striatal resting-state functional connectivity in patients with major depressive disorder[J]. Hum Brain Mapp,2019,40(11):3338-3346.

    (收稿日期:2019-05-28 修回日期:2019-10-21)

    (編辑:陈 宏), 百拇医药(刁云 杨航 舒云峰 杜彪)
上一页1 2 3 4 5